Possible effects of insulin-like growth factor-I, IGF-binding protein-3 and IGF-1/IGFBP-3 molar ratio on mammographic density: a cross-sectional study

The purpose of this study was to examine the possible effects of IGF-1, IGFBP-3 and IGF-1/IGFBP-3 molar ratio on manunographic density and assess whether this relationship was similar in subgroups of pre- and postmenopausal women. A group of 341 Italian women of childbearing age or naturally postmenopausal who had performed mammographic examination at the section of radiology of our department a maximum three months prior to recruitment were enrolled. A blood sample was drawn for determination of IGF-1, IGFBP-3 levels and IGF-1/IGFBP-3 molar ratio was calculated. On the basis of recent mammograms the women were divided into two groups: dense breast (DB) and non-dense breast (NDB). To assess the association between mammographic density and IGF-1, IGFBP-3 and Molar ratio Student's t-test was employed before and after stratified by menopausal status. The analysis of the relationship between mammographic density and plasma levels of IGF-1, IGFBP-3 and IGF-1/IGFBP-3 molar ratio showed that IGF-1 levels and molar ratio varied in the two groups resulting in higher mean values in the DB group whereas IGFBP-3 showed similar values in both groups (DB and NDB). After stratification of the study population by menopausal status, no association was found. Our study provides strong evidence of a crude association between breast density, and plasma levels of IGF-1 and molar ratio. IGF-1 and molar ratio might increase mammographic density and thus the risk of developing breast cancer.

IGF-1; IGFBP-3; IGF-1/IGFBP-3; Molar ratio; Mammographic density; Breast cancer risk

[1] Wood T.L., Yee D.: “Introduction: IGFs and IGFBPs in the normal mammary gland and in breast cancer”. J. Mammary Gland. Biol. Neoplasia, 2000, 5, 1.

[2] Sachdev D., Yee D.: “The IGF system and breast cancer”. Endocr. Relat. Cancer, 2001, 8, 197.

[3] Mikami K., Ozasa K., Nakao M., Miki T., Hayashi K., Watanabe Y. et al., JACC Study Group: “Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan”. Asian Pac. J. Cancer Prev., 2009, 10 (suppl.), 57.

[4] Bostedt K.T., Schmid C., Ghirlanda-Keller C., Olie R., Winterhalter KH, Zapf J.: “Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells”. Exp. Cell Res., 2001, 271, 368.

[5] Li B.D., Khosravi M.J., Berkel H.J., Diamandi A., Dayton M.A., Smith M.H.: “Free insulin-like growth factor-I and breast cancer risk”. Int. J. Cancer, 2001, 91, 736.

[6] Pollak M.N., Schernhammer E.S., Hankinson S.E.: “Insulin-like growth factors and neoplasia”. Nat. Rev. Cancer, 2004, 4, 505.

[7] O’Han M.K., Baxter R.C., Schedlich L.J.: “Effects of endogenous insulin-like growth factor binding protein-3 on cell cycle regulation in breast cancer cells”. Growth Factors, 2009, 12, 1.

[8] Helle S.I.: “The insulin-like growth factor system in advanced breast cancer”. Best. Pract. Clin. Endocrinol. Metab., 2004, 18, 67.

[9] Jerome L., Shiry L., Leyland-Jones B.: “Anti-insulin-like growth factor strategies in breast cancer”. Semin. Oncol., 2004, 31, 54.

[10] Firth S.M., Baxter R.C.: “Cellular actions of the insulin-like growth factor binding proteins”. Endocr. Rev., 2002, 23, 824.

[11] Siwanowicz I., Popowicz G.M., Wisniewska M., Huber R., Kuenkele K.P., Lang K. et al.: “Structural basis for the regulation of insulin-like growth factors by IGF binding proteins”. Structure, 2005, 13, 155.

[12] Endogenous Hormones and Breast Cancer Collaborative Group, Key T.J., Appleby P.N., Reeves G.K., Roddam A.W.: “Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies”. Lancet Oncol., 2010, 11, 530.

[13] Baglietto L., Dallas R. English, Hopper J.L., Morris H.A., Tilley W.D., Giles G.G.: “Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer”. Cancer Epidemiol. Biomarkers Prev., 2007, 16, 763.

[14] Taverne C.W., Verheus M., McKay J.D., Kaaks R., Canzian F., Grobbee D.E. et al.: “Common genetic variation of insulin-like growth factor-binding protein 1 (IGFBP-1), IGFBP-3, and acid labile subunit in relation to serum IGF -I levels and mammographic density”. Breast Cancer Res. Treat., 2010, 123, 843.

[15] Shi R., Yu H., McLarty J., Glass J.: “IGF-I and breast cancer: a meta-analysis”. Int. J. Cancer, 2004, 111, 418.

[16] Mathews L., Schneider S.S.: “Insulin-like growth factor-I inhibits growth regulatory responses engaged by estrogen and progesterone in the mouse mammary gland”. Eur. J. Cancer Prev., 2008, 17, 297.

[17] Johansson H., Gandini S., Bonanni B., Mariette F., Guerrieri-Gonzaga A., Serrano D. et al.: “Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women”. Breast Cancer Res. Treat., 2008, 108, 57.

[18] Schernhammer E.S., Holly J.M., Pollak M.N., Hankinson S.: “Circulating levels of insulin-like growth Factors, their Binding Proteins, and breast cancer risk”. Cancer Epidemiol Biomarkers Prev., 2005, 14.

[19] Schernhammer E.S., Holly J.M., Hunter D.J., Pollak M.N., Hankinson S.E.: “Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II”. Endocrine-related Cancer, 2006, 13, 583.

[20] Harvey J.A., Bovbjerg V.E.: “Quantitative assessment of mammographic breast density: relationship with breast cancer risk”. Radiology, 2004, 230, 29.

[21] Boyd N.F., Guo H., Martin L.J., Sun L., Stone J., Fishell E. et al.: “Mammographic density and the risk and detection of breast cancer”. N. Engl. J. Med., 2007, 356, 227.

[22] Vachon M.C., van Gils C.H., Sellers T.A., Ghosh K., Pruthi S., Brandt K.R., Pankratz V.S.: “Mammographic density, breast cancer risk and risk prediction”. Breast Cancer Res., 2007, 9, 217.

[23] Boyd N.F., Rommens J.M., Vogt K., Lee V., Hopper J.L., Yaffe M.J., Paterson A.D.: “Mammographic breast density as an intermediate phenotype for breast cancer”. Lancet Oncol., 2005, 6, 798.

[24] McCormack V.A., dos Santos Silva I.: “Breast density and parenchymal patterns as markers of breast cancer risk: a metaanalysis”. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 1159.

[25] Byrne C., Colditz G.A., Willett W.C., Speizer F.E., Pollk M., Hankinson S.E.: “Plasma insulin growth factor (IGF-I), IGF -binding protein 3, and mammographic density”. Cancer Res., 2000, 60, 3744.

[26] Diorio C., Pollak M., Byrne C., Mâsse B., Herbert-Croteau N., Yaffe M. et al.: “Insulin-like growth factor-1, IGF-binding protein-3, and mammographic breast density”. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 1065.

[27] Maskarinec G., Williams A.E., Kaas R.: “A cross-sectional investigation of breast density and insulin-like growth factor I”. Int. J. Cancer, 2003, 107, 991.

[28] dos Santos Silva I., Johnson N., De Stavola B., Torres-Mejìa G., Fletcher O., Allen N.E. et al.: “The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women”. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 449.

[29] Bremnes Y., Ursin G., Bjurstam N., Rinaldi S., Kaaks R., Gram I.T.: “Endogenous sex hormones, prolactin and mammographic density in postmenopausal Norwegian women. International journal of cancer”. Int. J. Cancer, 2007, 121, 2506.

[30] Bremnes Y., Ursin G., Bjurstam N., Rinaldi S., Kaaks R., Gram I.T.: “Insulin-like growth factor and mammographic density in postmenopausal Norwegian women”. Cancer Epidemiol. Biomarkers Prev., 2007, 16, 57.

[31] Aiello E.J., Tworoger S.S., Yasui Y., Stanczyk F.Z., Potter J., Ulrich C.M. et al.: “Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women”. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 1411.

[32] Liberman L., Menell J.H.: “Breast imaging reporting and data system (BIRADS)”. Radiol. Clin. North Am., 2002, 40, 409.

[33] Balleyguier C., Ayadi S., Nguyen K.V., Vanel D., Dromain C., Sigal R.: “BIRADSTM classification in mammography”. EJR, 2007, 61, 192.

[34] Yu H., Jin F., Shu X.O., Li B.D., Dai Q., Cheng J.R. et al.: “Insulin-like growth factors and breast cancer risk in Chinese women”. Cancer Epidemiol. Biomarkers Prev., 2002, 11, 705.

[35] Maskarinec G., Takata Y., Chen Z., Gram I.T., Nagata C., Pagano I. et al.: “IGF-I and mammographic density in four geographic locations: a pooled analysis”. Int. J. Cancer, 2007, 121, 1786.

[36] Campagnoli C., Abbà C., Ambroggio S., Peris C.: “Differential effects of progestins on the circulating IGF-I system”. Maturitas, 2003, 10, 46 (suppl. 1), S39.

[37] Chia V.M., Newcomb P.A., White E., Zheng Y., Potter J.D., Lampe J.W.: “Reproducibility of serum leptin, insulin-like growth factor-I, and insulin-like growth factor-binding protein-3 measurements”. Horm. Res., 2008, 69, 295.

[38] Borofsky N.D., Vogelman J.H., Krajcik R.A., Orentreich N.: “Utility of insulin-like growth factor-1 as a biomarker in epidemiological studies”. Clin. Chem., 2002, 48, 2248.

[39] Milani D., Carmichael J.D., Welkowitz J., Ferris S., Reitz R.E., Danoff A., Kleinberg D.L.: “Variability and reliability of single serum IGF -measurements: impact on determining predictability of risk ratios in disease development”. J. Clin. Endocrinol. Metab., 2004, 89, 2271.

[40] Dabrosin C.: “Increase of free insulin-like growth factor-1 in normal human breast in vivo late in menstrual cycle”. Breast Cancer Res. Treat., 2003, 80, 193.

[41] Friedrich N., Krebs A., Nauck M., Wallaschofski H.: “Age- and gender-specific reference ranges for serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 concentrations on the Immulite 2500: results of the Study of Health in Pomerania (SHIP)”. Clin. Chem. Lab. Med., 2010, 48, 115.

[42] Yaffe M.J.: “Mammographic density. Measurement of mammographic density”. Breast Cancer Res., 2008, 10, 209.

[43] Martin L.J., Melnichouk O., Guo H., Chiarelli A.M., Hislop T.G., Yaffe M.J. et al.: “Family history, mammographic density, and risk of breast cancer”. Cancer Epidemiol. Biomarkers Prev., 2010, 19, 456.

[44] Boyd N.F., Lockwood G.A., Martin L.J., Byng J.W., Yaffe M.J., Tritchler D.L.: “Mammographic density as a marker of susceptibility to breast cancer: a hypothesis”. IARC Sci. Publ., 2001, 154, 163.

[45] Diorio C., Brisson J., Bérubé S., Pollak M.: “Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels”. Cancer Epidemiol. Biomarkers Prev., 2008, 17, 880.

[46] Diorio C., Brisson J., Bérubé S., Pollak M.: “Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional study”. Breast Cancer Res., 2008, 10, R42.